Another phase II trial [145] evaluated the combination of trastuzumab plus FOLFOX (leucovorin calcium, fluorouracil, oxaliplatin) in patients with HER2-positive (IHC 2+ or IHC 3+) metastatic colorectal cancer as second- or third-line therapy. This evidence concerns the gene ERBB2 and metastatic colorectal cancer.